W.K. Kellogg Foundation Trust Sells 114,583 K Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
The W.K. Kellogg Foundation Trust, listed as a director and >10% owner of Kellanova (K), reported a sale of 114,583 shares of Kellanova common stock on 08/21/2025 at a reported price of $79.982 per share. After the sale the Trust beneficially owned 45,212,037 shares. The filing states the sales were made pursuant to trading instructions given by the Trust on May 7, 2024 intended to comply with Rule 10b5-1(c). The Form 4 is signed by Craig R. Carberry, as corporate trustee representative.
Positive
- Transaction executed under a Rule 10b5-1(c) plan, indicating adherence to an established trading instruction dated May 7, 2024
- Clear post-transaction disclosure showing the Trust still beneficially owns 45,212,037 shares
Negative
- None.
Insights
TL;DR: A trustee-led sale under a 10b5-1 plan reduced holdings modestly; filing shows compliance with an established trading program.
The Form 4 discloses a non-derivative disposition of 114,583 shares at $79.982 on 08/21/2025 by the W.K. Kellogg Foundation Trust, which remains a substantial holder with 45,212,037 shares beneficially owned. The filing explicitly references trading instructions dated May 7, 2024 and Rule 10b5-1(c), indicating the trade was executed under a pre-established plan designed to provide the affirmative defense to insider trading claims. From a compliance perspective, the disclosure is thorough: it lists the reporting parties, transaction details, post-transaction holdings, and the trustee signature, which supports regulatory transparency.
TL;DR: The sale is recorded but the Trust remains a large shareholder; transaction appears routine and pre-planned.
The Trust's disposition of 114,583 shares represents a small fraction of its remaining 45.2 million-share position. The Form 4 clarifies that the W.K. Kellogg Foundation is the sole beneficiary and names the trustees. The presence of a 10b5-1(c) instruction dated May 7, 2024 signals the trade followed a predetermined schedule rather than opportunistic insider activity. For investors tracking insider activity, this is a documented, procedural sale rather than a sudden, unexplained disposal.